In this context, CD8+ T cells in the tumor core likely have a more direct impact on limiting tumor progression and improving survival, while stromal CD8+ cells have less prognostic relevance due to the generally lower immune activity in this subtype. This evidence concerns the gene CD8A and neoplasm.